An executive action undertaken during the Trump administration aimed to alter the landscape of pharmaceutical costs and accessibility. One specific area addressed was methods of determining what patients pay for their medications, potentially changing the role of pharmacy benefit managers. These measures sought to introduce greater transparency into pricing structures and potentially reduce out-of-pocket expenses for consumers.
Such governmental directives have the potential to significantly impact the pharmaceutical industry, influencing drug pricing, manufacturer revenue, and patient access. Historically, previous administrations have also attempted to address healthcare costs through various legislative and executive means. The potential benefit of this type of directive is the lowering of medication costs for individuals, increased market competition among drug manufacturers, and a simplification of complex pricing schemes.
